Semaglutide

Wegovy, also called Semaglutide, is a drug used to treat type 2 diabetes and reduce obesity. It was developed by Novo Nordisk in 2012. It was approved for use in America in 2017. It was approved in Europe in 2022 and in the National Health Service in 2023. 
People who had the weekly injection, saw their weight drop by 12% on average after 68 weeks.